TrialAnnals of the rheumatic diseases2022

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.

Ian N Bruce et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.